Table 2. . Duration and persistence of treatments per study group after propensity score matching.
| Study groups PSM Patients |
Apixaban (n = 2160) | Acenocoumarol (n = 2160) | p-value |
|---|---|---|---|
| Time since diagnosis, years | |||
| Mean (SD) | 0.9 (1.4) | 0.9 (1.5) | 0.611 |
| Median (P25–P75) | 0.1 (0.0–1.8) | 0.1 (0.0–1.9) | |
| Treatment duration, days | |||
| Mean (SD) | 300.3 (104.0) | 266.4 (121.1) | <0.001 |
| Median (P25–P75) | 330 (216–365) | 304 (136–365) | |
| Previous use of antithrombotic medication | |||
| Acenocoumarol initial | 28.2% | 100.0% | 0.001 |
| Apixaban | 71.8% | 0.0% | 0.001 |
| Not treatment persistence at 1 year | 28.9% | 39.4% | <0.001 |
| Treatment abandonment | 5.6% | 5.2% | 0.570 |
| Dose reduction | 2.2% | 7.2% | <0.001 |
| Switch to heparin | 6.5% | 5.5% | 0.421 |
| Switch to antiplatelet | 11.3% | 4.3% | <0.001 |
| Switch to other NOAC | 3.3% | 17.2% | <0.001 |
| Treatment persistence | |||
| 6 months | 79.8% | 70.4%† | <0.001 |
| 12 months | 71.1% | 60.6%‡ | <0.001 |
| Mortality | 3.7% | 8.3% | <0.001 |
Values expressed as a percentage or mean (SD).
†
HR: 1.2 (95% CI: 1.0–1.3) p = 0.006.
‡
HR: 1.3 (95% CI: 1.1–1.4) p = 0.012.
CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; HR: Hazard ratio; DOAC: Non-vitamin K antagonist oral anticoagulants; p: statistical significance; P: Percentile; PSM: Propensity score matching; SD: Standard deviation.